Diurnal Group PLC Shares and AJ Bell Investor Evening Webinar

TIDMDNL

Diurnal Group PLC

24 February 2021

24 February 2021

Diurnal Group plc

("Diurnal" or the "Company")

Diurnal to present at Shares and AJ Bell Investor Evening Webinar

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will be presenting at the Shares and AJ Bell investor evening webinar on Tuesday 02 March 2021. The webinar will start at 18:00 GMT and investors can register to attend here: https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-020321 .

Martin Whitaker, Chief Executive Officer of Diurnal, will be presenting an overview of the Company and will be available to take questions during the event.

 
 For further information, please visit www.diurnal.co.uk or 
  contact: 
 
                                                   [phone] 
 Diurnal Group plc                                  1000 
 Martin Whitaker, Chief Executive Officer 
 Richard Bungay, Chief Financial Officer 
 
 Panmure Gordon (UK) Limited (Nominated Adviser    [phone] 
  and Sole Broker)                                  2500 
 Corporate Finance: Freddy Crossley, Emma Earl 
 Corporate Broking: Rupert Dearden 
 
                                                   [phone] 
 FTI Consulting (Media and Investor Relations)      1000 
 Simon Conway 
 Victoria Foster Mitchell 
 

Notes to Editors

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-headquartered, European specialty pharma company developing hormone therapeutics for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency and hypogonadism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRATJMFTMTTTBAB

(END) Dow Jones Newswires

February 24, 2021 02:00 ET (07:00 GMT)